RAPT Therapeutics, Inc. (RAPT) Net Income (Loss) Attributable to Parent USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
RAPT Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • RAPT Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$30.5 M, a 4.27% decline year-over-year.
  • RAPT Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$118 M, a 27.4% decline year-over-year.
  • RAPT Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$117 M, a 39.3% decline from 2022.
  • RAPT Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$83.8 M, a 21.1% decline from 2021.
  • RAPT Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$69.2 M, a 30.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$118 M -$30.5 M -$1.25 M -4.27% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$117 M -$30.9 M -$7.93 M -34.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$109 M -$31.4 M -$10.1 M -47.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$98.7 M -$25.3 M -$6.1 M -31.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-13
Q1 2023 -$92.6 M -$29.3 M -$8.8 M -43% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$83.8 M -$23 M -$5.02 M -28% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$78.8 M -$21.2 M -$2.58 M -13.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$76.2 M -$19.2 M -$3.07 M -19.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$73.2 M -$20.5 M -$3.95 M -23.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$69.2 M -$17.9 M -$5.19 M -40.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 -$64 M -$18.7 M -$4.02 M -27.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$60 M -$16.1 M -$3.72 M -30.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$56.3 M -$16.5 M -$3.38 M -25.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$52.9 M -$12.7 M +$481 K +3.64% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$53.4 M -$14.6 M -$4.66 M -46.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$48.7 M -$12.4 M -$1.77 M -16.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$46.9 M -$13.1 M -$3.95 M -43% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$43 M -$13.2 M -$3.79 M -40.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$39.2 M -$9.97 M +$313 K +3.04% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$39.5 M -$10.6 M -$2.42 M -29.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-16
Q1 2019 -$37.1 M -$9.19 M -$956 K -11.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-16
Q4 2018 -$36.1 M -$9.43 M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 -$10.3 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-12-11
Q2 2018 -$8.2 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-12-11
Q1 2018 -$8.23 M Jan 1, 2018 Mar 31, 2018 10-Q 2019-12-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.